Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 5/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.50 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739035 | 0.91 | MEN1 (0.59) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL30947438 | 0.83 | LMNA (0.78) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL739301 | 0.82 | MEN1 (0.63) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL10833938 | 0.82 | CYP1A2 (0.63) | LMNAHPGDALDH1A1MAPTTSHR | |
| Trifluoroacetic Acid SCHEMBL4607803 | 0.82 | MEN1 (0.49) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL28775863 | 0.81 | LMNA (0.52) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL891454 | 0.80 | LMNA (0.69) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL6902600 | 0.80 | RAB9A (0.72) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL738053 | 0.79 | MEN1 (0.59) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL1838349 | 0.79 | RAB9A (0.70) | LMNAHPGDALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794154-B1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-7939658-B2 | Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-7534789-B2 | Enantiomeric pure β agonists, manufacturing and use as a medicament thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| EP-1996581-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1986644-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | Boehringer Ingelheim International GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| US-7429583-B2 | Betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| WO-2007104772-A9 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070249595-A1 | Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | US | disclosed |
| WO-2007104772-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| WO-2007093608-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| EP-1794154-A1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032627-A1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-23 | — | — | US | disclosed |
| US-4363814-A | VASODILATORS AND CNS STIMULANTS | BOEHRINGER INGELHEIM GMBH (DE) | 1982-12-14 | — | — | US | disclosed |
| US-4271158-A | Vasodilating or antidepressant phenalkanolaminoalkyl-substituted imidazolidinones | BOEHRINGER INGELHEIM GMBH (US) | 1981-06-02 | — | — | US | disclosed |
| US-4215119-A | VASODILATORS, ANTIDEPRESSANTS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-07-29 | — | — | US | disclosed |
| US-4154829-A | ANTIDEPRESSANT, VASODILATION | BOEHRINGER INGELHEIM GMBH (DE) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | CHRM1, ADRB1, ADRA1B | LMNA 269/4885HPGD 1383/4885ALDH1A1 1726/4885 |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | ADRB1, ADRB2, ADRA1B | LMNA 413/4885HPGD 1694/4885ALDH1A1 2339/4885 |
| US-20070249595-A1 | Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof | ADRB1, ADRA1B, ADRA2B | LMNA 416/4885HPGD 1651/4885ALDH1A1 2222/4885 |
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | CHRM1, CHRM2, MTNR1B | LMNA 245/4885HPGD 792/4885ALDH1A1 993/4885 |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | CHRM1, CHRM2, MTNR1B | LMNA 245/4885HPGD 792/4885ALDH1A1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.